Big pharma companies are in an ROI rut. But that doesn’t mean drug developers at large are grappling with a midlife crisis. In fact, the young guns of the industry—upstart biotechs—aren’t doing too shabby, according to a new Iqvia Institute report. There have been a few notable shifts in drug development ... Read More »

Nearly two months after biotechnology company Monsanto rejected a $62 billion takeover offer from Bayer AG, the German pharmaceutical company said Thursday it has upped the proposal by about $3 billion. On July 1, Bayer offered shareholders of Missouri-based Monsanto $125 per stock share, which is $3 per share higher ... Read More »

Mind loss of life is normally seen as crossing the ultimate frontier of life, as a minimum in a clinicalplacing. until a affected person has gone via mind demise, we believe that a few vestige of theirpersonality need to nevertheless be in there. however damage to the CNS, specifically axonal ... Read More »